|Dr. Richard Murray||Pres, CEO & Director||750.26k||N/A||1959|
|Mr. Hugh M. Cole||Chief Bus. Officer & Head of Corp. Devel.||250.79k||N/A||1965|
|Dr. Elizabeth G. Tréhu||Chief Medical Officer||513.56k||N/A||1960|
|Dr. James P. Allison||Founder||N/A||N/A||N/A|
|Dr. Thomas F. Gajewski||Founder||N/A||N/A||N/A|
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.